As at 27 May 2020, the number of shares in issue was 397,921,969.
On 12 May 2020 the Company announced that it has raised £2,500,000 (before expenses) through an oversubscribed placing of 35,714,286 ordinary shares of 1p each (the “Placing Shares”) at a price of 7p per share (the “Placing Price”). The fundraise is conditional on shareholders approving the special resolution to be proposed at the Company’s Annual General Meeting (“AGM”) to be held on 4 June 2020 inter alia allowing the Directors to issue equity securities for cash.
An application will be made for the Placing Shares to be admitted to the Official List of the UK Listing Authority by way of a Standard Listing (“Admission”) and it is expected that Admission will become effective and that dealing in the Placing Shares will commence on or around 5 June 2020. The Placing Shares will rank pari passu with the existing ordinary shares of the Company.
Following Admission of these shares and shares allotted pursuant to an exercise of warrants that took place on 18 May 2020, the enlarged issued share capital of the Company will comprise 433,636,255 ordinary shares of 1p each. No ordinary shares are held in Treasury. The total number of voting rights in the Company will therefore be 433,636,255 after Admission and the figure of 433,636,255 ordinary shares may then be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.
As at 27 May 2020
As at 27 May 2020
|Dr Vladislav Sandler||41,544,677||10.44|
Shares Not In Public Hands
Insofar as it is aware, as at 27 May 2020, 54.50% of the Company’s securities were not in public hands.
UK City Code On Takeovers And Mergers
The Company is subject to the provisions of the City Code on Takeovers and Mergers.
|12 May 2020||Notice of AGM to be held on 4 June 2020|
Other Exchanges And Trading Platforms
Hemogenyx Pharmaceuticals plc has not applied or agreed to have any of it securities admitted or traded on any other exchanges or trading platforms.